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Abstract
Background: Prostate volume can affect whether patients qualify for brachytherapy (desired size ≥20 mL
and ≤60 mL) and/or active surveillance (desired PSA density ≤0.15 for very low risk disease). This study examines
variability in prostate volume measurements depending on imaging modality used (ultrasound versus MRI) and
volume calculation technique (contouring versus ellipsoid) and quantifies the impact of this variability on
treatment recommendations for men with favorable-risk prostate cancer.
Methods: We examined 70 patients who presented consecutively for consideration of brachytherapy for favorable-risk
prostate cancer who had volume estimates by three methods: contoured axial ultrasound slices, ultrasound ellipsoid
(height × width × length × 0.523) calculation, and endorectal coil MRI (erMRI) ellipsoid calculation.
Results: Average gland size by the contoured ultrasound, ellipsoid ultrasound, and erMRI methods were 33.99, 37.16,
and 39.62 mLs, respectively. All pairwise comparisons between methods were statistically significant (all p<0.015). Of
the 66 patients who volumetrically qualified for brachytherapy on ellipsoid ultrasound measures, 22 (33.33%) did not
qualify on ellipsoid erMRI or contoured ultrasound measures. 38 patients (54.28%) had PSA density ≤0.15 ng/dl as
calculated using ellipsoid ultrasound volumes, compared to 34 (48.57%) and 38 patients (54.28%) using contoured
ultrasound and ellipsoid erMRI volumes, respectively.
Conclusions: The ultrasound ellipsoid and erMRI ellipsoid methods appeared to overestimate ultrasound contoured
volume by an average of 9.34% and 16.57% respectively. 33.33% of those who qualified for brachytherapy based on
ellipsoid ultrasound volume would be disqualified based on ultrasound contoured and/or erMRI ellipsoid volume. As
treatment recommendations increasingly rely on estimates of prostate size, clinicians must consider method of volume
estimation.
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Eligibility for both brachytherapy [1] and active surveil-
lance in men with favorable-risk prostate cancer is par-
tially dependent on determination of prostate volume
[2]. Desired volumes for brachytherapy are typically cited
as ≥20 mL [3-5] and ≤60 mL [1], while classification into
the “very low-risk” group that is often offered active sur-
veillance requires a PSA density of ≤0.15 ng/dl, calcu-
lated on the basis of measured prostate volume [2].
Despite the dependence of treatment recommendations
on prostate volume, the method by which the volume
should be estimated is rarely specified in guidelines.
Three major techniques are currently in widespread
use to determine prostate size. From a transrectal ultra-
sound (TRUS), volume can be estimated via the trad-
itional ellipsoid estimation based on the height (H),
width (W), and length (L) of the prostate, using the for-
mula: H × W × L × 0.523. Alternatively, the same TRUS
can be contoured on multiple axial slices (of thickness
typically between 2.5 mm and 5 mm) during a brachy-
therapy volume study and then integrated in 3D space
to generate a contoured volume estimate. Finally, MRIs
are being increasingly used to stage prostate cancer and
commonly report volume estimates based on the ellips-
oid formula.
There have been some studies examining the differ-
ences between the volume estimates of these various
modalities [6-11], but currently it is unknown whether
differences in the methods of volume determination
could translate into differences in treatment recommen-
dations for favorable-risk patients.
Therefore, our study aimed to assess whether differ-
ences in prostate volume as estimated by use of the ellips-
oid formula based on TRUS measurements, contouring
on TRUS, and use of the ellipsoid formula based on mea-
surements from endorectal coil MRI (erMRI) would have
implications for the determination of the eligibility of men
with favorable-risk prostate cancer for either brachyther-
apy or active surveillance.
Methods
Institutional Review Board approval was obtained from
the Dana-Farber Cancer Institute. The study examined
70 men who presented consecutively to one of the au-
thors (PLN, Dana-Farber Cancer Institute) for consider-
ation of brachytherapy for the treatment of favorable
risk prostate cancer and had three estimates of prostate
volume from the ellipsoid TRUS method, contoured
TRUS method, and ellipsoid erMRI method with avail-
able MRI dimensions.
From an initial pool of 90 consecutive men, eight
men who received Dutasteride or Androgen Deprivation
Therapy were excluded from consideration owing to the
role of these therapies in altering prostate size, as was
the one individual who presented for consideration of
salvage, rather than first-line, therapy. Patients who did
not have all three measures of volume or for whom
erMRI height, width, and length measures were not
available (n =11) were excluded, leaving 70 patients for
whom all data was available.
All individuals included in the analysis underwent
prostate volume studies between August 2009 and June
2011. Volume studies typically included 3 separate vol-
ume estimates made at the time of presentation, and
typically occurred on the same day. Ultrasound studies
were performed in the dorsal lithotomy position with a
BK probe ® (BK Medical, Peabody, MA) connected to a
Nucletron FIRST system with SPOT-PRO v3.1 ™ (Nucle-
tron, an Elekta company, Elekta AB, Stockholm, Sweden)
for acquiring ultrasound information in the sagittal
plane and generating a 3D reconstruction for axial con-
touring. Volume was evaluated according to the ellips-
oid method, in which height, width, and length were
used to calculate overall gland volume based on the
standard BK ultrasound prostate volume formula, namely
H × W × L × 0.523. Contouring was done on the recon-
structed ultrasound axial slices (2.5 mm thickness), and
was also used to estimate volume based on an integration
of the slices by the FIRST system (Nucletron, an Elekta
Company). Additionally, patients underwent a 3Tesla
multiparametric T2 erMRI, from which prostate volume
was calculated using the standard MRI ellipsoid formula
of H × W × L × 0.523.
Desired size for brachytherapy was taken to be be-
tween ≥20 mL [3-5] and ≤60 mL [1]. PSA densities were
calculated using the latest PSA values available at the
time of consideration for brachytherapy. Absolute PSA
was divided by measured gland volume to obtain dens-
ity. In keeping with the National Comprehensive Cancer
Network (NCCN) Guidelines ® (NCCN, Fort Washing-
ton, PA), PSA density of ≤0.15 was regarded as a cut-off
for the “very low risk” group that is typically offered
active surveillance [2].
Prostate volumes and PSA densities obtained using the
different calculations of gland size were compared using
standard, paired t-tests carried out with STATA soft-
ware. P-values of less than 0.05 were said to reflect stat-
istical significance.
Results
Variation in Prostate Size by Method of Estimation
Estimates of prostate volume differed when disparate
scanning modalities were used. Average gland size calcu-
lated by the contoured ultrasound, ellipsoid ultrasound,
and erMRI methods were 33.99, 37.16, and 39.62 mLs,
respectively. The difference between the average volume
obtained on contoured ultrasound and that obtained on
ellipsoid ultrasound was significant (p=0.00) (Figure 1)
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toured ultrasound and erMRI (p=0.00). The comparison
between average ellipsoid and erMRI prostate volumes
was also significant (p=0.01) (Figure 2).
Impact of Estimation Method on Qualification for
Brachytherapy
Different numbers of patients fit the prostate volume eli-
gibility criteria for brachytherapy when disparate scan-
ning modalities were used to calculate gland size. Of
the 70 patients examined, all except 4 were eligible for
brachytherapy when prostate volumes were calculated
using the ellipsoid ultrasound method (desirable volume
≥20 mL and ≤60 mL). Of the 4 patients deemed ineli-
gible on ellipsoid ultrasound measures, 2 (50%) met
eligibility criteria for brachytherapy based on erMRI
measures of volume.
Among the remaining 66 patients deemed anatomical
candidates for brachytherapy based on ellipsoid ultra-
sound measures (size≥20 mL and ≤60 mL), 22 (33.33%)
did not qualify for brachytherapy based on volumes mea-
sured using one or both of the other scanning modalities.
In particular, 16 patients would not have qualified on
erMRI (6 patients <20 mL, 10 patients >60 mL) and 10 pa-
tients would not have qualified based on contoured ultra-
sound measures (7 patients <20 mL, 3 patients >60 mL).
Figure 1 Differences in prostate volume measures using ellipsoid ultrasound versus contoured ultrasound.
Figure 2 Differences in prostate volume measures using ellipsoid ultrasound and erMRI.
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for brachytherapy as determined by the ellipsoid ultra-
sound technique for measuring prostate volume had
prostates <20 mL on erMRI (9.09%) and 10 patients had
glands measuring >60 mL on erMRI (15.15%). 7 of the
66 patients who were anatomically good candidates
for brachytherapy on ellipsoid ultrasound had prostate
sizes <20 mL (10.61%) on contoured ultrasound, and 3
patients had volumes >60 mL (4.55%).
In total, the management of 24/70 patients (34.29%)
would have changed if patient prostate size had been mea-
sured by a method other than ellipsoid TRUS (Figure 3).
Impact of Estimation Method on PSA Density
Each of the different scanning modalities was also used to
calculate a PSA density. Using ellipsoid ultrasound vol-
umes, 38 patients (54.28%) had a PSA density ≤0.15 ng/dl,
which is the cut-off for the very low-risk group that is
commonly offered active surveillance [2]. When vol-
ume was determined by erMRI, 34 patients (48.57%)
were deemed to have PSA density ≤ 0.15 ng/dl, while
38 patients (54.28%) were categorized as having PSA
density≤0.15 ng/dl using contoured ultrasound estimates
of volume.
Discussion
Determination of eligibility for brachytherapy generally
relies on prostate volume based criteria [1,3-5], but there
are no agreed upon guidelines for how volume should
be measured. Studies have examined the potential im-
pact of large gland size on accurate dosimetry [12],
pubic arch interference [13,14], as well as urinary reten-
tion [12,14-16]. The technical feasibility of accurate dos-
imetry and effective outcomes [6,13,17-19] in men with
smaller prostates who receive brachytherapy has also
been analyzed. Previous studies of the impact of prostate
volume on brachytherapy dosimetry and complication
rates have used numerous methods to determine vol-
ume, including contoured TRUS [14-16,18,20], ellipsoid
TRUS [21], and MRI [22,23].
In our study, the ellipsoid ultrasound and ellipsoid
erMRI methods overestimated TRUS contoured volume
by an average of 9.34% and 16.57%, respectively. These
results reflect the fact that no prostate is an exact ellips-
oid, and while formulas based solely on height, width,
and length are very convenient, they can only approxi-
mate the volume. Contouring on thinly cut axial slices
can account for variability in prostate shape from the
base to the apex [24].
While previous studies of volume estimation in
brachytherapy candidates have shown smaller differences
between TRUS and MRI-based estimations than our
findings [7-9], most studies have compared TRUS to
contoured MRI, which is less clinically practical than
using an ellipsoid estimation of volume on MRI. The
one study to compare volumes derived from contouring
on TRUS with ellipsoid MRI volumes in 15 patients who
were not receiving hormone therapy found a correlation
between volumes of r=0.83 [10].
In our study, volumes estimated by erMRI were larger
than those calculated on TRUS by either contouring or
the ellipsoid method. These results may reflect the fact
that MRI enables better soft tissue density determin-
ation, leading to greater maximal dimension estimates
and inflating calculated volume estimates. It may also
reflect the fact that on MRI, transagittal cuts are some-
times used for height estimates, rather than the transax-
ial cuts used on TRUS. Previous work has demonstrated
that such a distinction in means of measuring height can
alter volume estimates [25].
Our study is unique in that it may be the first to quan-
tify the impact of differences in volumes derived from
disparate scanning modalities on decision-making sur-
rounding candidacy for brachytherapy. Of patients who
qualified for brachytherapy based on the commonly used
ellipsoid ultrasound technique for volume estimation,
33.33% would not have qualified for brachytherapy were
they assessed using ultrasound contoured and/or erMRI
estimated volumes. Management of 34.29% of patients
Figure 3 Eligibility for brachytherapy.
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method other than ellipsoid TRUS.
We also examined the impact of different volume
measures on patients’ eligibility for active surveillance
based on standard PSA density criteria (desired PSA
density ≤ 0.15 ng/dl), and found that while 54.28% of pa-
tients were eligible using ellipsoid TRUS measures,
54.28% and 48.57% were eligible using erMRI and con-
toured ultrasound measures, respectively. The one previ-
ous study of active surveillance eligibility demonstrated
that of five patients who were initially enrolled in an ac-
tive surveillance program but were found to be ineligible
based on contoured MRI, one patient (20%) would still
have been eligible based on ellipsoid TRUS [11]. Our
study differs in our use of ellipsoid rather than con-
toured MRI as well as the diversity of our cohort, which
was not limited solely to patients already enrolled in an
active surveillance program.
The practical implications of our study are that clini-
cians should be aware that volume estimates of prostate
size can vary significantly depending on how the esti-
mate was obtained, and so when treatment decisions are
highly dependent on prostate size, it may be worthwhile
to consider the source of the estimate and how close the
estimate sits to the boundary of a clinical guideline. For
example, a patient with a prostate size of 70 cc estimated
on a prostate MRI who is otherwise a great candidate
for brachytherapy might only have a volume of 55 cc on
a contoured ultrasound.
While our study is the largest to examine differences
in prostate volume among brachytherapy candidates
using disparate imaging modalities, it also has certain
limitations. First, all cases were drawn from a single
medical center with imaging carried out and inter-
preted at the center. Secondly, the ultrasound and
erMRI scans done on our patients were not all carried
out at precisely the same time, leading to possible
confounding by bladder filling. However, scans were
typically performed on the same day and endorectal
coil was used in an effort to improve the accuracy of
all MRI scans [26,27].
Conclusions
Our results point to significant differences in treatment
recommendations depending on which imaging modality
is used. In patients in whom prostate volume measure-
ments or PSA density numbers are borderline for eligi-
bility for brachytherapy or active surveillance, clinicians
may wish to consider the possibility that disparate scan-
ning modalities could yield different volume estimates.
As treatment recommendations increasingly depend on
prostate size, clinicians will need to take into account
the method by which volume was estimated in deter-
mining treatment plans.
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